vs
珐博进（KYNB）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是珐博进的1.1倍（$27.1M vs $25.4M），Rumble Inc.净利率更高（-120.8% vs -129.8%，领先9.1%），Rumble Inc.同比增速更快（-10.5% vs -29.9%），Rumble Inc.自由现金流更多（$-31.7M vs $-59.3M），过去两年Rumble Inc.的营收复合增速更高（15.2% vs -7.8%）
珐博进是一家生物制药企业，专注于纤维化疾病、贫血、肿瘤领域创新疗法的研发与商业化，核心产品罗沙司他已在中国、日本等多个市场获批上市，为患者提供全新治疗选择。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
KYNB vs RUM — 直观对比
营收规模更大
RUM
是对方的1.1倍
$25.4M
营收增速更快
RUM
高出19.4%
-29.9%
净利率更高
RUM
高出9.1%
-129.8%
自由现金流更多
RUM
多$27.6M
$-59.3M
两年增速更快
RUM
近两年复合增速
-7.8%
损益表 — Q1 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.4M | $27.1M |
| 净利润 | $-32.9M | $-32.7M |
| 毛利率 | 15.9% | 5.5% |
| 营业利润率 | -193.9% | -131.1% |
| 净利率 | -129.8% | -120.8% |
| 营收同比 | -29.9% | -10.5% |
| 净利润同比 | 57.1% | 86.2% |
| 每股收益（稀释后） | $-0.33 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KYNBRUM
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $24.8M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $30.2M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | $25.4M | $17.7M | ||
| Q4 23 | $-73.8M | $20.4M |
净利润KYNBRUM
| Q4 25 | — | $-32.7M | ||
| Q3 25 | — | $-16.3M | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $-236.8M | ||
| Q3 24 | — | $-31.5M | ||
| Q2 24 | — | $-26.8M | ||
| Q1 24 | $-32.9M | $-43.3M | ||
| Q4 23 | $-56.2M | $-29.3M |
毛利率KYNBRUM
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | 15.9% | -79.5% | ||
| Q4 23 | — | — |
营业利润率KYNBRUM
| Q4 25 | — | -131.1% | ||
| Q3 25 | — | -113.6% | ||
| Q1 25 | — | -153.5% | ||
| Q4 24 | — | -80.1% | ||
| Q3 24 | — | -131.0% | ||
| Q2 24 | — | -172.7% | ||
| Q1 24 | -193.9% | -197.4% | ||
| Q4 23 | 128.8% | -182.5% |
净利率KYNBRUM
| Q4 25 | — | -120.8% | ||
| Q3 25 | — | -65.7% | ||
| Q1 25 | — | -11.2% | ||
| Q4 24 | — | -783.2% | ||
| Q3 24 | — | -125.9% | ||
| Q2 24 | — | -119.2% | ||
| Q1 24 | -129.8% | -244.1% | ||
| Q4 23 | 76.2% | -143.6% |
每股收益（稀释后）KYNBRUM
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $-1.17 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | $-0.33 | $-0.21 | ||
| Q4 23 | $-0.56 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.6M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-228.1M | $274.8M |
| 总资产 | $365.9M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KYNBRUM
| Q4 25 | — | $237.9M | ||
| Q3 25 | — | $269.8M | ||
| Q1 25 | — | $301.3M | ||
| Q4 24 | — | $114.0M | ||
| Q3 24 | — | $132.0M | ||
| Q2 24 | — | $154.2M | ||
| Q1 24 | $177.6M | $183.8M | ||
| Q4 23 | $203.5M | $219.5M |
股东权益KYNBRUM
| Q4 25 | — | $274.8M | ||
| Q3 25 | — | $302.2M | ||
| Q1 25 | — | $339.6M | ||
| Q4 24 | — | $-63.1M | ||
| Q3 24 | — | $166.1M | ||
| Q2 24 | — | $192.7M | ||
| Q1 24 | $-228.1M | $210.7M | ||
| Q4 23 | $-204.2M | $251.6M |
总资产KYNBRUM
| Q4 25 | — | $336.8M | ||
| Q3 25 | — | $367.2M | ||
| Q1 25 | — | $391.1M | ||
| Q4 24 | — | $195.3M | ||
| Q3 24 | — | $217.2M | ||
| Q2 24 | — | $243.2M | ||
| Q1 24 | $365.9M | $263.0M | ||
| Q4 23 | $423.5M | $295.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.3M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-59.3M | $-31.7M |
| 自由现金流率自由现金流/营收 | -233.9% | -117.2% |
| 资本支出强度资本支出/营收 | 0.1% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-274.7M | $-70.8M |
8季度趋势，按日历期对齐
经营现金流KYNBRUM
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-10.6M | ||
| Q1 25 | — | $-14.5M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | $-59.3M | $-33.9M | ||
| Q4 23 | $-18.3M | $-33.1M |
自由现金流KYNBRUM
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q1 25 | — | $-14.6M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-23.1M | ||
| Q1 24 | $-59.3M | $-34.3M | ||
| Q4 23 | $-18.6M | $-36.6M |
自由现金流率KYNBRUM
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q1 25 | — | -61.7% | ||
| Q4 24 | — | -40.9% | ||
| Q3 24 | — | -79.5% | ||
| Q2 24 | — | -102.8% | ||
| Q1 24 | -233.9% | -193.3% | ||
| Q4 23 | 25.2% | -179.7% |
资本支出强度KYNBRUM
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 6.1% | ||
| Q1 24 | 0.1% | 2.4% | ||
| Q4 23 | -0.3% | 17.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
